Aerovate Therapeutics, Inc. (AVTE) DCF Valuation

Aerovate Therapeutics, Inc. (AVTE) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Aerovate Therapeutics, Inc. (AVTE) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess Aerovate Therapeutics, Inc.'s intrinsic value? Our (AVTE) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and enhance your investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA .0 -8.9 -23.0 -53.2 -81.3 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation 3.3 .0 .0 .1 .1 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -3.3 -8.9 -23.0 -53.2 -81.4 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 3.5 4.6 167.4 129.2 122.4 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .5 .6 1.2 2.6 2.4 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 -.2 -.2 -.1 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % -0.07420659 -0.07420659 -0.07420659 -0.07420659 -0.07420659 -0.07420659 -0.07420659 -0.07420659 -0.07420659 -0.07420659
EBITAT -3.3 -8.4 -23.0 -53.3 -81.5 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF .5 -8.3 -22.6 -52.0 -81.7 -2.4 .0 .0 .0 .0
WACC, % 9.12 9.12 9.12 9.12 9.12 9.12 9.12 9.12 9.12 9.12
PV UFCF
SUM PV UFCF -2.2
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -2
Net Debt -23
Equity Value 21
Diluted Shares Outstanding, MM 26
Equity Value Per Share 0.78

What You Will Receive

  • Customizable Excel Template: A fully editable Excel-based DCF Calculator featuring pre-filled financial data for Aerovate Therapeutics, Inc. (AVTE).
  • Accurate Data: Historical performance metrics and forward-looking projections (highlighted in the yellow cells).
  • Assumption Flexibility: Modify key forecast parameters such as revenue growth, EBITDA %, and WACC.
  • Instant Calculations: Quickly assess how your inputs affect Aerovate's valuation.
  • Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
  • Intuitive Layout: Organized for clarity and ease of navigation, complete with step-by-step guidance.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Aerovate Therapeutics, Inc. (AVTE).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
  • Customizable Forecast Assumptions: Easily modify growth rates, research and development expenses, and discount rates.
  • Integrated Financial Ratios: Assess profitability, leverage, and efficiency ratios relevant to Aerovate Therapeutics, Inc. (AVTE).
  • Interactive Dashboard and Charts: Visual representations highlight essential valuation metrics for streamlined analysis.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Aerovate Therapeutics' (AVTE) data.
  • Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view updated results, including Aerovate Therapeutics' intrinsic value.
  • Step 5: Make well-informed investment decisions or create reports based on the outputs.

Why Choose Aerovate Therapeutics Calculator?

  • Accuracy: Utilizes real Aerovate financial data for precise calculations.
  • Flexibility: Tailored for users to easily adjust and experiment with inputs.
  • Time-Saving: Avoid the complexities of constructing a financial model from the ground up.
  • Professional-Grade: Crafted with the expertise and detail expected at the CFO level.
  • User-Friendly: Intuitive design makes it accessible for all users, regardless of financial background.

Who Should Use This Product?

  • Biotech Students: Understand drug development processes and apply them using real-world case studies.
  • Researchers: Integrate advanced models into your studies or clinical trials.
  • Investors: Evaluate your investment strategies and analyze valuation trends for Aerovate Therapeutics, Inc. (AVTE).
  • Market Analysts: Enhance your analysis with a comprehensive, customizable financial model.
  • Healthcare Entrepreneurs: Discover how large biotech firms like Aerovate Therapeutics are assessed and valued.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Aerovate Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Aerovate Therapeutics, Inc. (AVTE).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

Es wurden keine passenden Produkte gefunden.